Serum Concentration of Reg IV in Patients with Colorectal Cancer: Overexpression and High Serum Levels of Reg IV Are Associated with Liver Metastasis

Oncology ◽  
2007 ◽  
Vol 72 (5-6) ◽  
pp. 371-380 ◽  
Author(s):  
Naohide Oue ◽  
Hiroki Kuniyasu ◽  
Tsuyoshi Noguchi ◽  
Kazuhiro Sentani ◽  
Masanori Ito ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Serum Concentration ◽  
Serum Levels ◽  
High Serum

scholarly journals Prognostic meaning of tissue inhibitors of matrix metalloproteinases TIMP-1 and TIMP-2 in patients with colorectal cancer

2020 ◽  
Vol 66 (1) ◽  
pp. 25-32
Author(s):  
Elena Kostova ◽  
Slavica Shubeska Stratrova
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Prognostic Markers ◽  
Distant Metastases ◽  
Serum Levels ◽  
Pathological Stage ◽  
Chemotherapy Treatment ◽  
Blood Tests ◽  
Keywords Colorectal Cancer

The aim of this study was to analyze TIMP-1 and TIMP-2 serum levels in patients with colorectal cancer (CRC) and to correlate the results with the pathological stage of the disease and outcome in order to evaluate the role of TIMP-1 and TIMP-2 serum levels as prognostic markers. The investigation has been made on 82 patients with operable CRC without distant metastases, who had undergone blood tests in order to determine the TIMP-1 and TIMP-2 serum levels in the following points of time: preoperatively, as well as 3, 6, 9 and 12 months postoperatively. Significant differences were found between serum levels of TIMP-1 and TIMP-2 obtained preoperatively and postoperatively, as well as significant association of serum TIMP-1 levels obtained preoperatively in CRC patients in stage I and III, in the 3th and in the 6th month (p<0.001) postoperatively as defined points of time with the outcome of CRC patients. Serum TIMP-2 levels obtained preoperatively was significantly associated with the outcome of the CRC patients. Analysis of the obtained TIMP-1 and TIMP-2 serum levels in CRC patients showed statistically significant differences with: disease progression, occurrence of liver metastasis, prior to and post chemotherapy treatment. The results derived a conclusion that the serum levels of TIMP-1 and TIMP-2 could be indicators for occurrence and progression of CRC, as well as valuable and useful markers for following the effects of chemotherapy treatment. Keywords: colorectal cancer, TIMP-1, TIMP-2, prognosis

scholarly journals Correlation analysis between liver metastasis and serum levels of miR-200 and miR-141 in patients with colorectal cancer

2017 ◽  
Vol 16 (5) ◽  
pp. 7791-7795 ◽  
Author(s):  
Meng Ding ◽  
Tao Zhang ◽  
Shijie Li ◽  
Ying Zhang ◽  
Yunfeng Qiu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Correlation Analysis ◽  
Serum Levels

scholarly journals Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4842
Author(s):  
Hidetaka Suzuki ◽  
Shuichi Mitsunaga ◽  
Masafumi Ikeda ◽  
Takao Aoyama ◽  
Kazumi Yoshizawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Group Performance ◽  
Performance Status ◽  
Advanced Pancreatic Cancer ◽  
Serum Levels ◽  
Pancreatic Disease ◽  
High Serum ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor

We aimed to evaluate the association of circulating growth differentiation factor 15 (GDF-15) with cachexia symptoms and the biological activity of advanced pancreatic cancer (APC). Treatment-naïve patients with liver metastasis of APC or with benign pancreatic disease were retrospectively analyzed. Clinical data, blood samples, and biopsy specimens of liver metastasis were collected prior to anti-cancer treatment. Serum GDF-15 levels and multiple protein expressions in lysates extracted from liver metastasis were measured by enzyme-linked immuno-sorbent assay and reverse-phase protein array, respectively. The cut-off for serum GDF-15 was determined as 3356.6 pg/mL, the mean plus two standard deviations for benign pancreatic disease. The high-GDF-15 group was characterized as showing low Karnofsky performance status (KPS) (p = 0.037), poor Eastern Cooperative Oncology Group performance status (ECOG-PS) (p = 0.049), severe appetite loss (p = 0.011), and high serum levels of carbohydrate antigen 19-9 (p = 0.019) and C-reactive protein (p = 0.009). Tumors of the high-GDF-15 group expressed high levels of phosphorylated (p)JNK (p = 0.007) and pAkt (p = 0.040). APC patients with high serum GDF-15 showed signatures of cachexia and activation of the signaling pathways involving Akt and JNK in the tumor. This study indicated circulating GDF-15 could be associated with cachectic symptoms in APC.

scholarly journals Serum homocysteine may related to colorectal adenoma number: a cross-sectional study

2020 ◽  
Author(s):  
Jing-Wei Wang ◽  
Ya-Dan Wang ◽  
Jing Wu ◽  
Feng-Xiao Dong ◽  
Lin Lin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Colorectal Adenoma ◽  
Intraepithelial Neoplasia ◽  
Serum Levels ◽  
High Serum ◽  
Serum Biomarkers ◽  
Cross Sectional ◽  
Colon Adenomas ◽  
Serum Homocysteine

Abstract BackgroundEarly detection of high-risk adenomas is crucial for the prevention of colorectal cancer. The aim of the study was to evaluate the usefulness of serum biomarkers in characterizing the histological features of colon adenomas and predicting the progression of high-risk adenomas to colorectal cancer.MethodsPatients diagnosed with colorectal adenoma in Beijing Shijitan Hospital between Jan 2013 and Dec 2015 were recruited to the study. Patients were classified into low-, moderate-, and high-risk according to the adenoma scores. Erythrocyte sedimentation rate (ESR), clinical biochemistry, serum homocysteine (HCY) levels, and serum tumor markers were determined. Multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression. The correlation between the serum biomarkers and basic characteristic of the adenomas was analyzed.ResultsThe serum levels of HCY (OR=0.06, 95% CI 0.01-1.52), CA724 (OR=0.03, 95% CI 0.00-0.97), and ESR (OR=0.01, 95% CI 0.00-0.44) were positively correlated with the risk of colon adenomas developing into colorectal cancers. High serum level of HCY was related with the development of multiple (>3) adenomas (OR=0.25, 95% CI 0.11-0.56). Higher ESR was related to the occurrence of high-grade intraepithelial neoplasia (OR=0.06, 95% CI 0.00-0.73) and villous adenomas (OR=0.20, 95% CI 0.04-0.98).ConclusionSerum levels of HCY, ESR and CA724 may be valuable indicators for predicting the risk of colon adenomas, among them, ESR may be more related to specific pathology types, HCY is more related to the number of adenomas and development of colorectal cancer.

Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15110-e15110
Author(s):  
T. Ochiai ◽  
K. Nishimura ◽  
T. Watanabe ◽  
M. Kitajima ◽  
N. Nakayama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Serum Iron ◽  
Biological Response ◽  
Serum Levels ◽  
High Serum ◽  
Iron Level ◽  
Iron Group ◽  
Survival Times ◽  
High Increase ◽  
Serum Iron Level

e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985). However, the correlation to prognosis has not been evaluated. The aim of this study was to evaluate the correlation between prognosis and serum-iron level in advanced / metastatic colorectal cancer (aCRC / mCRC) patients treated by FOLFOX / FOLFIRI. Methods: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008. 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis. These patients were categorized into the high increase group and the low increase group using 200% increase as cut-off value and the prognosis was compared. Results: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001). This increase was transient and returns to pre chemotherapy level by the start of next course. This alteration was always observed on the chemotherapy. The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004). The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed. Conclusions: It is suggested that serum-iron increase is a biological response not attributed to leakage from erythrocyte and hepatocyte. Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy. No significant financial relationships to disclose.

scholarly journals Serum level of miR-142-3p predicts prognostic outcome for colorectal cancer following curative resection

2019 ◽  
Vol 47 (5) ◽  
pp. 2116-2125 ◽  
Author(s):  
Wencang Gao ◽  
Dexiang Pang ◽  
Senquan Yu
Keyword(s):  
Colorectal Cancer ◽  
Cancer Survival ◽  
Tumor Resection ◽  
Serum Levels ◽  
High Serum ◽  
Serum Samples ◽  
Prognostic Outcome ◽  
Polymerase Chain ◽  
Diagnostic And Prognostic Value ◽  
Low Serum

Objective MicroRNA (miR)-142-3p may function as a tumor suppressor in the development of various cancers. In this study, we measured serum levels of miR-142-3p in patients with colorectal cancer (CRC) to evaluate the diagnostic and prognostic value of miR-142-3p. Methods Serum samples from 363 consecutive CRC patients and 156 healthy controls were retrospectively collected. Serum miR-142-3p levels were measured using real-time quantitative reverse transcription polymerase chain reaction. All patients were followed up regularly after tumor resection. The correlation between serum miR-142-3p level and survival outcomes was analyzed. Results Serum levels of miR-142-3p were significantly lower in CRC patients than in healthy volunteers. A low serum miR-142-3p level was significantly associated with advanced cancer. Survival analysis demonstrated that patients with a low serum miR-142-3p had a lower 5-year overall survival rate than patients with a high serum miR-142-3p level (67.4% vs. 76.9%). Serum miR-142-3p level was also shown to be an independent risk factor for CRC in multivariate analysis (hazard ratio, 2.68; 95% confidence interval: 1.21–7.95). Conclusions Serum miR-142-3p might serve as a useful diagnostic and prognostic marker for CRC.

Use of serum CXCL16 to predict liver metastasis and prognosis in colorectal cancer patients.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 424-424
Author(s):  
K. Matsushita ◽  
Y. Toiyama ◽  
K. Tanaka ◽  
H. Yasuda ◽  
S. Saigusa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
Serum Levels ◽  
Migration And Invasion ◽  
Poor Survival ◽  
Normal Volunteers ◽  
Colorectal Cancer Patients

424 Background: Colorectal cancer (CRC) is one of the major causes of cancer death worldwide. In CRC, serum levels of CEA have become well-established prognostic indicators. However, it is not generally accepted as optimal in its prognostic power. The aim of this study was to identify novel and reliable serum prognostic markers. Methods: We performed cytokine array to identify novel prognostic serum marker, and CXCL16 was selected. To investigate the relationships between sCXCL16 and clinicopathological findings including survival, the serum levels of CXCL16 in 237 CRC patients and 20 normal volunteers were assessed by enzyme-linked immunosorbent assay. Furthermore, we investigated proliferation, invasion and wound healing assay to investigate the biological role of CXCL16 to colon cancer cell by recombinant CXCL16 exposing to HT-29. Results: The mean sCXCL16 concentration in patients was significantly higher than that in normal volunteers (p<0.0001). In addition, sCXCL16 levels increased significantly in accordance with the progression of UICC stage classification (p < 0.05). In clinicopathologic findings, sCXCL16 was significantly associated with the presence of lymph node (p=0.019) and the presence of liver metastases (p=0.011). Elevated sCXCL16 level demonstrated a significant association with poor survival, and was an independent risk factor for poor survival. Furthermore, sCXCL16 was an independent marker for predicting liver metastasis (logistic analysis; p=0.0015). In vitro, recombinant CXCL16 promoted epithelial mesencymal transition (EMT) phenotype characterized by impaired E-cadherin and induction of Vimentin. In addition, CXCL16 promoted cell growth, migration and invasion. Conclusions: Our data demonstrate that preoperative sCXCL16 level increased in colorectal cancer patients, and that sCXCL16 correlated with liver metastasis, and is an independent prognostic factor for overall survival. Elevated CXCL16 has been proposed as a useful predictive marker for liver metastasis and overall survival in CRC. In vitro, CXCL16/CXCR6 axis might play an importance role in mediating cell survival, migration and invasion by EMT in CRC cell. No significant financial relationships to disclose.

Importance of serum VEGF and basic FGF levels in determining response to treatment and survival in patients with metastatic colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21050-e21050 ◽  
Author(s):  
Muge Keskin ◽  
Zeki Ustuner ◽  
Murat Dincer ◽  
Durmus Etiz ◽  
H.Eray Celik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Serum Levels ◽  
High Serum ◽  
Response To Treatment ◽  
Basic Fgf ◽  
Bevacizumab Treatment ◽  
Pre Treatment ◽  
Vegf Level ◽  
Pretreatment Serum

e21050 Background: Colorectal cancer has an important place in worldwide death from cancer causes. Angiogenesis, in which angiogenic factors such as VEGF and basic FGF have a key role, is an important factor in patient survival with respect to progression and metastatic spreading in colorectal cancer. In this study, we aimed to determine that whether serum VEGF and bFGF pre- and post-treatment serum levels are decisive in evaluating response to treatment and progression in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI-bevacizumab. Methods: In 33 mCRC patients treated in our department serum VEGF and bFGF levels were monitored in the beginning of treatment and until progression during FOLFIRI-bevacizumab treatment before 4.-, 8.- and 12.-regimens. Serum levels of VEGF and bFGF were assssed using the quantitative sandwich enzyme immunoassay technique. Results: In our study serumVEGF and bFGF levels were significantly higher than the healthy controls (p<0.001). We found that the patients with pre-treatment high serum bFGF levels have significantly short PFS and with pre-treatment high serum LDH levels have significantly short overall survival (OS). In patients with pre-treatment low serum VEGF value (< 147.79 pg/ml) had significantly longer OS (27.93 vs 23.27 mounts, P:0.026) in metastatic rectum cancer. In multivariate analysis were found to be prognostic factors VEGF levels and side of tumor for PFS and VEGF levels and whether to be operated of tumor for OS. Conclusions: Serum VEGF level was detected to be one of the factors that determine PFS and OS in mCRC. Pretreatment serum bFGF levels were determined PFS and monitorization of serum bFGF during treatment was found to be releated to response to treatment. Pretreatment serum LDH level was detected to determine OS in metastatic CRC. Although there was no statistical significance, in mCRC patients, whose pretreatment serum VEGF were high, PSK was longer with bevacizumab treatment. The important of pretreatment high serum VEGF level to select for treatment of bevacizumab will be planed in metastatic CRC requires to be confirmed in comprehensive, prospective studies.

Preoperative serum microRNA-203 as a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 564-564
Author(s):  
Yuji Toiyama ◽  
Keun Hur ◽  
Yoshinaga Okugawa ◽  
C. Richard Boland ◽  
Ajay Goel
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Cancer Metastasis ◽  
Culture Media ◽  
Predictive Biomarker ◽  
High Serum ◽  
Dependent Manner ◽  
Poor Survival ◽  
Mesenchymal Transition ◽  
Clinicopathological Findings

564 Background: Distant metastasis is the major causes of death in colorectal cancer (CRC) patients. Epithelial-mesenchymal transition (EMT) is a key process that converts polarized immotile epithelial cells into motile, invasive mesenchymal cells, enabling cancer cells to gain stem cell characteristics and an aggressive malignant phenotype such as metastasis. Mir-203 has been shown to directly suppress EMT activators such as ZEB2 and SNAI1/2. However, in spite of the key functional role of miR-203 in cancer metastasis, no previous studies have investigated the clinical significance of miR-203 in patients with CRC. Methods: To examine whether CRCs secret miR-203 in vitro and vivo,we first determined extracellular miR-203 levels in CRC cell culture media. Then, we quantified miR-203 levels in serum from mice with or without metastasis. Next, we investigated miR-203 expression in 58 pairs of primary CRC (pCRC) and corresponding matching liver metastasis (LM), as well as 186 serum and 154 matched tissue specimens from CRC patients. Results: HT-29 cells released miR-203 into culture media, which was dependent on cell number and duration of culture. In addition, high serum miR-203 levels were observed in mice with liver metastasis compared to control animals (p=0.0181). Mir-203 expression was significantly upregulated in LM compared to matching pCRC tissues (p=0.0002). Serum miR-203 was significantly upregulated in a tumor stage-dependent manner (p=0.0070), and high miR-203 expression was associated with poor survival in CRC patients (p<0.0001). In contrast to serum, no significant association between miR-203 expression in CRC tissues and clinicopathological findings was recognized. High serum miR-203 expression was an independent risk factor for poor prognosis (HR=2.1) as well as metastasis to lymph nodes (OR=2.5), liver (OR=6.2), peritoneum (OR=7.2), and distant organs (OR=4.4), respectively. Conclusions: High levels of serum miR-203, which may be derived from several metastatic sites, are associated with poor survival and metastasis, suggesting it is a promising non-invasive prognostic and metastasis-predictive biomarker in patients with CRC.

Sign in / Sign up

Export Citation Format

Share Document